Piper Sandler initiated coverage on Tourmaline with a new price target
$TRML
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Piper Sandler initiated coverage of Tourmaline with a rating of Overweight and set a new price target of $65.00